Hypertension Guidelines 2017

Similar documents
HYPERTENSION: ARE WE GOING TOO LOW?

2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST

Summary, Scope, BP Classification, BP thresholds and Targets

New Hypertension Guidelines. Kofi Osei, MD

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Using the New Hypertension Guidelines

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Managing HTN in the Elderly: How Low to Go

Treating Hypertension in 2018: What Makes the Most Sense Today?

Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN

Blood Pressure LIMBO How Low To Go?

2017 High Blood Pressure Clinical Practice Guideline

Pharmacy Updates in Primary Care. Nathan Lamberton Assistant Professor

Retour sur le congrès de l AHA 2017

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

HYPERTENSION: UPDATE 2018

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Jared Moore, MD, FACP

Long-Term Care Updates

Blood Pressure Treatment in 2018

What s In the New Hypertension Guidelines?

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

Objectives. Describe results and implications of recent landmark hypertension trials

2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Systolic Blood Pressure Intervention Trial (SPRINT)

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Hypertension and the SPRINT Trial: Is Lower Better

Update on Current Trends in Hypertension Management

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

THE IMPACT OF HYPERTENSION GUIDELINES. Daniel Lackland

Hypertension JNC 8 (2014)

Managing Hypertension in 2018

T. Suithichaiyakul Cardiomed Chula

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension Management Controversies in the Elderly Patient

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Egyptian Hypertension Guidelines

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Combination Therapy for Hypertension

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston

The Latest Generation of Clinical

Antihypertensive Trial Design ALLHAT

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Blood Pressure Acre Surgery Diviash Thakrar

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Dr Doris M. W Kinuthia

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension Management: A Moving Target

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Blood Pressure Treatment Goals

Controlling Hypertension in Primary Care: Hitting a moving target?

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Randomized Design of ALLHAT BP Trial

The New Hypertension Guidelines

Diabetes and Hypertension

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

KDIGO Controversies Conference on Blood Pressure in CKD

Hypertension and Cardiovascular Disease

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

CONTRIBUTING FACTORS FOR STROKE:

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Renal Disease through the Ages: From Childbearing years to Old Age. Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician.

HEART HEALTH UPDATE 2018

Blood Pressure Targets: Where are We Now?

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Causes of Poor BP control Rates

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

major public health burden

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

Creative blood pressure management: whys and the tricks

In late 2017, the American College of Cardiology (ACC)

Aquifer Hypertension Guidelines Module

What s the evidence, why do guidelines differ, and what should the GP do?

Hypertension Update Background

CVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Updates in Cardiovascular Recommendations for Diabetic Patients

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Potential U.S. Population Impact of the 2017 American College of Cardiology/ American Heart Association High Blood Pressure Guideline

Transcription:

Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published, under the sponsorship of the National Heart, Lung, and Blood Institute (NHLBI). In subsequent years, a series of Joint National Committee (JNC) BP guidelines were published. The present guideline updates prior JNC reports. A comprehensive guideline for diagnosis, prevention, evaluation, treatment and strategies to improve control rates during hypertension treatment. What s New in the Definition of High Blood Pressure? As per the new classification of hypertension, the difference lies in the BP category by replacing prehypertension stage with the term Elevated BP and changing the definition of Stage 1 and Stage 2 hypertension SBP/DBP (mm Hg) JNC 7/8 (2014) ACC/ AHA (2017) < 120 & < 80 Normal BP Normal BP 120-129 & < 80 Prehypertension Elevated BP 130-139 or 80-89 Prehypertension Stage 1 Hypertension 140-159 or 90-99 Stage 1 Hypertension 160 or 100 Stage 2 Hypertension Stage 2 Hypertension *Adults with SBP and DBP in 2 categories should be designated to the higher BP category. BP indicates blood pressure (based on an average of 2 careful readings obtained on 2 occasions). DBP, diastolic blood pressure; and SBP systolic blood pressure.

Aiming for BP Target - History Repeats but Partly In ACC/AHA Hypertension 2017 guidelines, intensification of the BP targets are done which is partly similar to JNC 7 recommendations but more stringent as compared to JNC 8 recommendations Hypertensive patients JNC 7 Target BP goal to be achieved (SBP/DBP mmhg) JNC 8 Target BP goal to be achieved (SBP/DBP mmhg) ACC/AHA Target BP goal to be achieved (SBP/DBP mmhg) Elderly < 140/90 (Age 60 yrs) <150/90 (Age 60 yrs) < 130* (Age 65 yrs) Adults < 140/90 (Age < 60 yrs) < 140/90 (Age < 60 yrs) <130/80 (with/without clinical CVD or 10-year ASCVD risk 10%) Coronary Heart Disease Diabetes <130/80 < 140/90 <130/80 CKD *Both SBP and DBP increase linearly up to the fifth or sixth decade of life, after which DBP gradually decreases while SBP continues to rise. Thus, isolated systolic hypertension is the predominant form of hypertension in older persons. Treatment Recommendation: Is It Different? In ACC/AHA Hypertension 2017 guidelines, screening for and management of other modifiable CVD risk factors are recommended as many adult patients with hypertension have CVD risk factors; the table below provides a list of such modifiable and relatively fixed risk factors Modifiable Risk Factors* Current cigarette smoking, secondhand smoking Diabetes mellitus Dyslipidemia/hypercholester olemia Overweight/obesity Physical inactivity/low fitness Unhealthy diet CVD risk factors Relatively Fixed Risk Factors CKD Family history Increased age Low socioeconomic/educational status Male sex Obstructive sleep apnea Psychosocial stress *Factors that can be changed and, if changed, may reduce CVD risk. Factors that are difficult to change (CKD, low socioeconomic/educational status, obstructive sleep apnea, cannot be changed (family history, increased age, male sex), or, if changed through the use of current intervention techniques, may not reduce CVD risk (psychosocial stress).

Blood Pressure (BP) Thresholds and Recommendations for Treatment *Note that patients with DM or CKD are automatically placed in the high-risk category. For initiation of RAS inhibitor or diuretic therapy, assess blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy. 1Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes. Patients with stage 2 hypertension and BP 160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control BP.

Treatment of High BP ACC/AHA 2017 Hypertension Guidelines To know your ASCVD risk score, click on the link below http://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/

Comparing JNC 8 & ACC/AHA 2017 Kindly note that BP thresholds for initiating the treatment as well as the BP goals are different in the JNC 8 and ACC/AHA guidelines. The ACC/AHA guidelines have more stringent BP thresholds. Please refer to the BP thresholds and goals mentioned earlier.

ACC/AHA 2017 Hypertension guideline is an evidence-based review from the following bodies For any scientific queries on above topic Write to the Scientific Department at: